Supply Chain Shocks Emerge

Geopolitical shifts in West Asia have offered little immediate relief for India's pharmaceutical exports. While tensions may be easing, the disruptions reveal deep structural weaknesses in the export system. A quick rebound in exports and drug prices is unlikely because global supply chains are broken by conflict and higher logistics costs. This situation calls for a strategic rethink of how India sources and manufactures drugs, moving beyond just being cost-competitive to building more lasting resilience.

West Asia Market Hit by Rising Costs

West Asia is a significant market for Indian pharmaceuticals, making up about 5.6% of total exports. Countries like the UAE, Saudi Arabia, Oman, Kuwait, and Yemen depend on India for affordable generic drugs. However, disrupted shipping routes and greatly increased freight costs are causing problems. Freight charges have reportedly doubled, with added surcharges of $4,000-$8,000 per shipment, putting heavy pressure on exporters. Pharmexcil estimates these disruptions could cost the industry between ₹2,500 crore and ₹5,000 crore ($300-$600 million) if they continue through March. This is squeezing company profits and delaying payments, especially for firms that already bought raw materials at higher prices.

Reliance on Imported Ingredients Creates Risk

The crisis highlights a major existing vulnerability: India's heavy reliance on imported Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Nearly 70% of these essential drug components come from outside India, mainly China. China's large-scale API production offers significant cost advantages, making its supply chain a strategic point that global instability can easily disrupt. While India is known as the "Pharmacy of the World" for the sheer volume of generics it produces (20% globally), its market value ranking is lower. This cost-focused model has often depended on China's upstream manufacturing. However, past disruptions, including the COVID-19 pandemic, are pushing for change. Government programs like the Production Linked Incentive (PLI) scheme and plans for Bulk Drug Parks aim to boost domestic API production and lower import dependence, a strategy now seen as even more critical.

Broader Sector Growth Faces Challenges

Looking beyond immediate export challenges, the overall pharmaceutical sector is expected to see steady growth. ICRA forecasts 7-9% revenue growth in FY2026, driven by strong domestic demand and exports to Europe. However, the US market may see slower growth due to pricing challenges and regulatory reviews. Globally, Fitch Ratings expects mid-single-digit growth in medicine spending for 2026, fueled by innovation. But, policy uncertainty and efforts to make supply chains more regional could affect profits. A recent EU-India trade pact could help Indian exports to Europe by lowering tariffs. Yet, challenges remain, including geopolitical risks, supply chain issues, and the need for continuous innovation into higher-value products like biologics. The focus is shifting from just low costs to a broader strategy that includes quality, reliability, and supply chain strength. This transition will require significant investment and collaboration.

Deeper Supply Chain Weaknesses Exposed

The West Asian conflict is serving as a major test for India's pharmaceutical industry, revealing systemic risks beyond temporary shipping problems. The biggest weakness is the heavy reliance on China for most API and KSM imports. This reliance on a single country means that while finished drugs might be made in India, the critical upstream supply chain remains exposed. China's massive scale and government support allow it to offer much lower prices, a factor that has historically weakened domestic API production in India. Additionally, the emphasis on volume and cost has sometimes meant less focus on strict quality and regulatory compliance at some manufacturing sites, leading to past supply issues and reputational damage, as seen with FDA warning letters. The current global tensions, combined with higher energy and shipping costs, worsen these risks, increasing the chances of drug shortages and price swings worldwide. Efforts to become more self-reliant, such as PLI schemes, are crucial but will take time and significant investment to effectively reduce these risks, especially given strong global competition.

Building Resilience for Future Growth

India's pharmaceutical industry, which is projected to reach $130 billion by 2030, is at a crucial point. While exports have shown resilience, approaching $29 billion by February FY26, the industry needs to speed up its strategic changes. The way forward requires a two-pronged approach: boosting domestic production of APIs and KSMs to cover 80-90% of needs, and diversifying export markets and shipping routes to reduce the impact of geopolitical and supply chain disruptions. Analysts generally have a stable outlook for the sector, predicting continued growth fueled by innovation, higher-value products, and government backing. However, to maintain its global leadership, India must go beyond just offering competitive prices and become a leader in quality, reliability, and strong supply chain resilience.